ArticlePloS one2021
In vitro and in vivo antibacterial activity assays of carvacrol: A candidate for development of innovative treatments against KPC-producing Klebsiella pneumoniae.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Thymol and carvacrol againstFrontiers in pharmacology · 2024Pooled it
- Plant Monoterpenes Geraniol, Eugenol and Carvacrol Against Multidrug-Resistant ESKAPE Isolates from Surgical Wounds.Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Effect of Spices and Their Phytochemicals: A Novel Approach to Overcoming Antibiotic Resistance.MedComm · 2026Review
- Current progress in antibacterial agents for carbapenem-resistant enterobacterales.Frontiers in pharmacology · 2026Review
- Essential Oils as Antimicrobial Agents Against WHO Priority Bacterial Pathogens: A Strategic Review of In Vitro Clinical Efficacy, Innovations and Research Gaps.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial efficacy of cinnamaldehyde combined with polymyxin B against carbapenem- polymyxin-resistant Klebsiella pneumoniae.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Review
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Mechanisms of action and resistance prevention of synergistic thymol and carvacrol combinations with antibiotics in Staphylococcus aureus and Acinetobacter baumannii.Natural products and bioprospecting · 2025Article
- Antibacterial and antibiofilm efficacy of eugenol, carvacrol, and cinnamaldehyde against colistin-resistant Klebsiella pneumoniae.Molecular biology reports · 2025Article
- Biological Activity of Monoterpene-Based Scaffolds: A Natural Toolbox for Drug Discovery.Molecules (Basel, Switzerland) · 2025Review
- Harnessing Monoterpenes and Monoterpenoids as Weapons against Antimicrobial Resistance.Polish journal of microbiology · 2025Review
- Antibacterial Activity of Selected Essential Oil Components and Their Derivatives: A Review.Antibiotics (Basel, Switzerland) · 2025Review
- Plant-Origin Components: New Players to Combat Antibiotic Resistance inInternational journal of molecular sciences · 2024Review
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Comparative De Novo and Pan-Genome Analysis of MDR Nosocomial Bacteria Isolated from Hospitals in Jeddah, Saudi Arabia.Microorganisms · 2023Article
- Carvacrol-A Natural Phenolic Compound with Antimicrobial Properties.Antibiotics (Basel, Switzerland) · 2023Review
- Rapid-killing efficacy substantiates the antiseptic property of the synergistic combination of carvacrol and nerol against nosocomial pathogens.Archives of microbiology · 2022Article
- Current State of Knowledge Regarding WHO Critical Priority Pathogens: Mechanisms of Resistance and Proposed Solutions through Candidates Such as Essential Oils.Plants (Basel, Switzerland) · 2022Review
- Effects of intramuscularly injected plant-derived antimicrobials in the mouse model.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dissemination of carbapenem-resistant Klebsiella pneumoniae poses a threat to the successful treatment of bacterial diseases and increases the need for new antibacterial agents development. The objective of this study was to determine the antimicrobial activity of carvacrol against multidrug-resistant K. pneumoniae. Carbapenemase production was detected by MALDI-TOF. The PCR and sequencing showed that the blaKPC-2, blaOXA-48, blaNDM-1, blaCTX-M-8 genes were present in carbapenem-resistant K. pneumoniae strains. The polymyxin-resistant K. pneumoniae strain exhibited alterations in mgrB gene. The antimicrobial activity of carvacrol was evaluated in vitro using broth microdilution and time-kill methods. For this, carbapenem-resistant K. pneumoniae and polymyxin-resistant strains, were evaluated. The in vitro results showed that carvacrol had antimicrobial activity against all isolates evaluated. The survival curves showed that carvacrol eradicated all of the bacterial cells within 4 h. The antimicrobial effect of carvacrol in vivo was determined using a mouse model of infection with Klebsiella pneumoniae carbapenemase (KPC). The treatment with carvacrol was associated with increased survival, and significantly reduced bacterial load in peritoneal lavage. In addition, groups treated with carvacrol, had a significant reduction in the total numbers of white cell and significantly increased of platelets when compared to the untreated group. In vivo and in vitro studies showed that carvacrol regimens exhibited significant antimicrobial activity against KPC-producing K. pneumoniae, making it an interesting candidate for development of alternative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.